FDA Considers Approval of Bemotrizinol, a New Sunscreen Ingredient
The U.S. Food and Drug Administration (FDA) is evaluating the approval of bemotrizinol, a highly effective ultraviolet (UV) filter already used in Europe, Asia, and Australia. This marks a potential major shift in U.S. sunscreen regulations, which have not seen significant updates in over 25 years. Bemotrizinol is a broad-spectrum UV filter that protects against both UVA and UVB rays, offering enhanced photostability and the ability to stabilize other sunscreen ingredients. Dermatologists have welcomed this development, emphasizing its potential to improve sunscreen effectiveness and usability. Skin cancer remains the most common cancer in the U.S., with one in five Americans expected to develop it in their lifetime. The FDA's rigorous approval process for sunscreen ingredients has been criticized for delaying access to advanced options, but the potential approval of bemotrizinol could provide U.S. consumers with better sun protection and more appealing sunscreen formulations. 
